Moderna shares were hit a little over a month ago when the company cut its 2024 net sales guidance to a range of $3 billion to $3.5 billion from a previous $4 billion.

Shares of Moderna Inc. MRNA shed 2.96% to $69.86 Wednesday, on what proved to be an all-around dismal trading session for the ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

Moderna (NYSE: MRNA) stock plunged Thursday on news it will be slashing its research and development budget by about 20% over ...

Shares in Moderna tumbled 11% in pre-market trading on Thursday, after the US biotech detailed plans to cut its research budget by more than $1bn.

NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...

Bridgewater Associates slashed a stake in Apple, halved its Lilly investment, doubled down on Microsoft, and bought Moderna ...

Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending and pushed back its time frame for breaking even. The Cambridge-based company ...

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...

Present Market Standing of Moderna Trading volume stands at 5,013,059, with MRNA's price down by -2.52%, positioned at $68.1. RSI indicators show the stock to be may be approaching oversold. Earnings ...

Moderna is aiming to reduce its research and development budget by about 20pc over the next three years, as the company tries ...

Health Canada has authorized Moderna's updated COVID-19 vaccine to roll out in fall immunization campaigns. The new Spikevax ...